Acute Myeloid Leukemia (AML)
Secondary AML - Webinar 2025
Topic(s)
Acute Myeloid Leukemia (AML)
In this webinar, Drs. Fadi Haddad and Jayastu Senapati discuss the diagnosis secondary AML from MDS, treatment options available to patients and symptom management.
AAMDSIF Supports the Accelerating Kids' Access to Care Act
Original Publication Date
Article Source
Coalition Action
AAMDSIF Supports the Accelerating Kids' Access to Care Act. On March 26, 2025, AAMDSIF joined with 212 additional patient advocacy and medical center organizations in urging members of the US Congress to pass the Accelerating Kids’ Access to Care Act. Passage of this bill will…
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the
Original Publication Date
Article Source
External Web Content
ABSTRACT Patients (pts) with myelodysplasia-related AML (MR-AML) are now genetically recategorized, with three different groups in the International Consensus Classification: AML with mutated TP53 (TP53-AML), with myelodysplasia-related gene mutations (MR-GM AML), and with…
How I treat secondary acute myeloid leukemia
Original Publication Date
Article Source
External Web Content
Abstract Secondary acute myeloid leukemia (sAML) has traditionally been used to designate any AML disease arising from an antecedent hematologic disorder or after prior cytotoxic or radiation therapy. We now know sAML comprises multiple disease entities with distinct clinical and…
How I use maintenance therapy in acute myeloid leukemia
Original Publication Date
Article Source
External Web Content
Abstract Outcomes for acute myeloid leukemia (AML) have improved significantly in the past decade with the approval of novel therapeutics targeting diverse vulnerabilities of leukemic cells, expanded access to stem cell transplantation, and improved safety of transplantation…
TP53-Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis
Original Publication Date
Article Source
External Web Content
ABSTRACT Patients with TP53 mutations in acute myeloid leukemia (AML) and blast phase myeloproliferative neoplasms (MPN-BP) experience similar poor clinical outcomes. A retrospective analysis of 39 patients with TP53 mutations (23 with AML and 16 with MPN-BP) revealed comparable…
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
Original Publication Date
Article Source
External Web Content
Dear Editor, Secondary acute myeloid leukemia (sAML), a subset of AML, may arise from antecedent hematologic disorders (antecedent myelodysplastic syndrome or chronic myelomonocytic leukemia [A-MDS/CMML]) or complication of prior cytotoxic chemotherapy or radiation therapy…
Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study
Original Publication Date
Article Source
External Web Content
To the Editor, Core-binding factor acute myeloid leukemia (CBF-AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and is classified as favorable risk by the 2022 European LeukemiaNet (ELN) guidelines [1]. We have previously reported on outcomes of patients with…
2025 AAMDSIF Bone Marrow Failure Summit Acute Myeloid Leukemia Expert Panel
Topic(s)
Acute Myeloid Leukemia (AML)
Presenter(s)
Mikkael Sekeres, MD, MS
Kah Poh (Melissa) Loh, MBBCh BAO, MS, FACCC
Christopher Hourigan, DM, DPhil, FRCP
Noa Holtzman, MD
Watch AML experts at the 2025 AAMDSIF Bone Marrow Failure Summit translate and discuss the latest science to advance patient outcomes. This session is moderated by Mikkael Sekeres, MD, MS from the University of Miami. Session Topics: HMA + Ven vs. 7+3 vs. liposomal cytarabine…